Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

MLA

Li, Shujun, et al. “Targeted Inhibition of MiR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.” Frontiers in Genetics, vol. 10, Jan. 2020, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fgene.2019.01278.

APA

Li, S., Li, Q., Lü, J., Zhao, Q., Li, D., Shen, L., Wang, Z., Liu, J., Xie, D., Cho, W. C., Xu, S., & Yu, Z. (2020). Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells. Frontiers in Genetics, 10, 1–11. https://doi.org/10.3389/fgene.2019.01278

Chicago

Li, Shujun, Qun Li, Jinhui Lü, Qian Zhao, Danni Li, Lei Shen, Zhongrui Wang, et al. 2020. “Targeted Inhibition of MiR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.” Frontiers in Genetics 10 (January): 1–11. doi:10.3389/fgene.2019.01278.